SAS powers small and midsize biotech and pharmaceutical companies
Despite the recession, pharmaceutical and biotech companies continue to invest in discovery and development of advanced, life-saving therapies. Small and midsize life science firms, leading the quest to deliver innovative products, use SAS analytics to speed drug development and facilitate regulatory compliance.
“Drug discovery and clinical trials entail years of work and millions of start-up dollars,” said Jason Burke, Worldwide Director of Health and Life Sciences at SAS. “For small and midsize firms with limited capital and staffing, ease of regulatory compliance, analysis and insight is paramount. And new drugs from these startup firms are driving growth at many top 10 pharmaceutical companies today.”
“SAS is the de facto industry standard analysis tool for clinical information,” said Ron Ellis, CEO of Endocyte, one of the companies that have recently acquired SAS analytics. “We chose SAS because it makes no sense to invest millions of dollars in clinical studies and not use the best tool available, SAS, to analyze that data.”
SAS continues to expand its focus on the small-medium business (SMB) market. Its channel partner program and targeted SMB pricing bundles enable SAS resellers to deliver powerful SAS software to any industry, including life sciences. Part of SAS’ overall channel efforts, The SAS reseller program also includes service providers and OEMs, to increase SAS awareness to SMBs while generating new sales for SAS.
Source: SAS